| Literature DB >> 27194399 |
Hu Zhu1, Dipendra K Aryal1, Reid H J Olsen1, Daniel J Urban1, Amanda Swearingen2, Stacy Forbes2, Bryan L Roth1, Ute Hochgeschwender2.
Abstract
DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic β-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439-446, 2016.Entities:
Keywords: G protein-coupled receptors; GsD; chemogenetic; hM3Dq; hM4Di
Mesh:
Substances:
Year: 2016 PMID: 27194399 PMCID: PMC4990490 DOI: 10.1002/dvg.22949
Source DB: PubMed Journal: Genesis ISSN: 1526-954X Impact factor: 2.487